SBTX vs. BVXP, 4BB, CIR, AVCT, TILS, SCLP, VSN, MPH, HVO, and ORPH
Should you be buying SkinBioTherapeutics stock or one of its competitors? The main competitors of SkinBioTherapeutics include Bioventix (BVXP), 4basebio (4BB), Circassia Group (CIR), Avacta Group (AVCT), Tiziana Life Sciences (TILS), Scancell (SCLP), Verseon (VSN), Mereo BioPharma Group plc (MPH.L) (MPH), hVIVO (HVO), and Open Orphan (ORPH). These companies are all part of the "biotechnology" industry.
SkinBioTherapeutics vs. Its Competitors
Bioventix (LON:BVXP) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, community ranking, institutional ownership, earnings, valuation and dividends.
In the previous week, Bioventix had 2 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 2 mentions for Bioventix and 0 mentions for SkinBioTherapeutics. Bioventix's average media sentiment score of 0.30 beat SkinBioTherapeutics' score of 0.00 indicating that Bioventix is being referred to more favorably in the media.
Bioventix has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, SkinBioTherapeutics has a beta of 2.01, suggesting that its stock price is 101% more volatile than the S&P 500.
Bioventix received 45 more outperform votes than SkinBioTherapeutics when rated by MarketBeat users. However, 60.26% of users gave SkinBioTherapeutics an outperform vote while only 52.87% of users gave Bioventix an outperform vote.
Bioventix has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.
62.3% of Bioventix shares are owned by institutional investors. Comparatively, 16.6% of SkinBioTherapeutics shares are owned by institutional investors. 8.0% of Bioventix shares are owned by company insiders. Comparatively, 20.4% of SkinBioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Bioventix has a net margin of 59.51% compared to SkinBioTherapeutics' net margin of -237.95%. Bioventix's return on equity of 69.09% beat SkinBioTherapeutics' return on equity.
Summary
Bioventix beats SkinBioTherapeutics on 11 of the 15 factors compared between the two stocks.
Get SkinBioTherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SkinBioTherapeutics Competitors List
Related Companies and Tools
This page (LON:SBTX) was last updated on 6/15/2025 by MarketBeat.com Staff
Buy SBTX Stock Free SBTX Stock Alerts